- Home
- JHI vs BMEA Comparison
JHI vs BMEA Comparison
Compare JHI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- BMEA
- Stock Information
- Founded
- JHI 1971
- BMEA 2017
- Country
- JHI United States
- BMEA United States
- Employees
- JHI N/A
- BMEA N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- BMEA Health Care
- Exchange
- JHI Nasdaq
- BMEA Nasdaq
- Market Cap
- JHI 125.7M
- BMEA 114.3M
- IPO Year
- JHI N/A
- BMEA 2021
- Fundamental
- Price
- JHI $14.22
- BMEA $1.96
- Analyst Decision
- JHI
- BMEA Strong Buy
- Analyst Count
- JHI 0
- BMEA 10
- Target Price
- JHI N/A
- BMEA $15.70
- AVG Volume (30 Days)
- JHI 29.5K
- BMEA 614.1K
- Earning Date
- JHI 01-01-0001
- BMEA 10-28-2025
- Dividend Yield
- JHI 6.80%
- BMEA N/A
- EPS Growth
- JHI N/A
- BMEA N/A
- EPS
- JHI 1.05
- BMEA N/A
- Revenue
- JHI N/A
- BMEA N/A
- Revenue This Year
- JHI N/A
- BMEA N/A
- Revenue Next Year
- JHI N/A
- BMEA N/A
- P/E Ratio
- JHI $12.47
- BMEA N/A
- Revenue Growth
- JHI N/A
- BMEA N/A
- 52 Week Low
- JHI $11.63
- BMEA $1.29
- 52 Week High
- JHI $13.40
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- JHI 51.62
- BMEA 55.83
- Support Level
- JHI $14.14
- BMEA $1.86
- Resistance Level
- JHI $14.46
- BMEA $2.11
- Average True Range (ATR)
- JHI 0.12
- BMEA 0.12
- MACD
- JHI -0.01
- BMEA 0.01
- Stochastic Oscillator
- JHI 30.95
- BMEA 56.38
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.